

Serial No. 10/645,784

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claims 1-27. (Canceled).

28. (Previously Presented). The process of Claim 46, wherein step b of Claim 46 is carried out by:

- a. preparing a gene construct comprising a nucleic acid sequence encoding the peptide selected in step a of claim 46 adjacent to either the N-terminus or the C-terminus of a nucleic acid sequence encoding an Fc domain; and
- b. b.expressing the gene construct.

29. (Previously Presented). The process of Claim 28, wherein the gene construct is expressed in an E. coli cell.

30 – 39. (Canceled).

40. (Previously Presented). The process of Claim 46, wherein step a of Claim 46 is carried out by a process comprising:


- a. preparing a gene construct comprising a nucleic acid sequence encoding a first selected peptide and a nucleic acid sequence encoding an Fc domain;
- b. conducting a polymerase chain reaction using the gene construct and mutagenic primers, wherein
 - i) a first mutagenic primer comprises a nucleic acid sequence complementary to a sequence at or near the 5' end of a coding strand of the gene construct, and
 - ii) a second mutagenic primer comprises a nucleic acid sequence complementary to the 3' end of the noncoding strand of the gene construct.

41-45. (Canceled).

46. (Currently Amended). A process for preparing a pharmacologically active compound, which comprises:

Serial No. 10/645,784

- (a) selecting from a peptide phage display library at least one peptide sequence that modulates the activity of AGP-3;
- (b) preparing a compound incorporating at least one said selected peptide sequence, wherein the compound has of the formula



and multimers thereof, wherein:

F^1 is an Fc domain;

X^1 and X^2 are each independently selected from $-(L^1)_c-P^1$, $-(L^1)_c-P^1-(L^2)_d-P^2$, $-(L^1)_c-P^1-(L^2)_d-P^2-(L^3)_e-P^3$, and $-(L^1)_c-P^1-(L^2)_d-P^2-(L^3)_e-P^3-(L^4)_f-P^4$

P^1 , P^2 , P^3 , and P^4 are each independently the selected peptide sequences;

L^1 , L^2 , L^3 , and L^4 are each independently linkers; and

a, b, c, d, e, and f are each independently 0 or 1, provided that at least one of a and b is 1;

wherein "peptide" refers to molecules of 2 to 40 amino acids.


47. (Original). The process of Claim 46, wherein the compound prepared is of the formulae




or



48. (Original). The process of Claim 46, wherein the compound prepared is of the formulae



or



49. (Original). The process of Claim 46, wherein F^1 is an IgG Fc domain.

50. (Original). The process of Claim 46, wherein F^1 is an IgG1 Fc domain.

51. (Original). The process of Claim 46, wherein F^1 comprises the sequence of SEQ ID NO: 2.

Claims 52-62 (Canceled).

63. (Previously Presented). The process of Claim 46 wherein a is 1 and b is 0.

Serial No. 10/645,784

64. (Previously Presented). The process of Claim 46 wherein X^1 is $-(L^1)_c-P^1-(L^2)_d-P^2$.
65. (Previously Presented). The process of Claim 63 wherein X^1 is $-(L^1)_c-P^1-(L^2)_d-P^2$.
66. (Previously Presented). The process of Claim 65 wherein L^1 is (Gly)_s.
67. (Previously Presented). The process of Claim 65 wherein L^2 is (Gly)_s.
68. (Previously Presented). The process of Claim 66 wherein L^2 is (Gly)_s.
69. (Previously Presented). The process of Claim 46 wherein the library is a phage display library.
70. (Previously Presented). The process of Claim 65 wherein the library is a phage display library.
71. (Previously Presented). The process of Claim 68 wherein the library is a phage display library.
- 72.-79. (Canceled)